Weight Loss
For years, GLP-1 medications were studied almost exclusively through the lens of blood sugar control and weight loss. More recent large-scale cardiovascular outcome trials have started to shift that framing, showing reduced rates of major cardiac events in some at-risk populations taking these medications — independent of how much weight was lost.
The proposed mechanisms are still being studied, but researchers point to several plausible contributors: reduced inflammation, improved blood pressure, better blood sugar stability, and the indirect cardiovascular benefits of significant weight loss itself.
It's important to be precise about what this does and doesn't mean. These findings apply to specific patient populations studied in specific trials — they aren't a blanket claim that GLP-1s prevent heart disease for everyone. Your own cardiovascular risk factors, family history, and current health status all matter for whether this is relevant to you.
If heart health is part of why you're considering a GLP-1 medication, that's worth raising directly with your provider so they can factor your full cardiac risk profile into the conversation.